FDA 483 OBSERVATION · #294 OF 1,945 MOST-CITED
Procedures To Be in Writing
FDA cited this observation 99 times across 96 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 4.9× the rate of the average FDA-cited firm (38.5% vs 7.8%), across 96 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Written procedures are lacking which describe in sufficient detail the identification, storage, testing, approval and rejection of components, drug product containers and closures.
Written procedures are lacking which describe in sufficient detail the testing of components.
Written procedures are lacking which describe in sufficient detail the receipt, testing, approval and rejection of components and drug product containers.
Written procedures are lacking which describe in sufficient detail the receipt, identification, storage, handling, sampling, testing, approval and rejection of components, drug product containers and closures.
Written procedures are lacking which describe in sufficient detail the receipt, identification, storage, handling, sampling, testing, approval and rejection of components and drug product containers.
Written procedures are lacking which describe in sufficient detail the receipt, identification, storage, handling, sampling, testing, approval and rejection of components, drug product containers and closures.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →